Zacks: Autolus Therapeutics Ltd – (AUTL) Given $37.50 Average Target Price by Analysts

Autolus Therapeutics Ltd – (NASDAQ:AUTL) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus target price of $37.50 for the company, according to Zacks. Zacks has also given Autolus Therapeutics an industry rank of 79 out of 255 based on the ratings given to related companies.

AUTL has been the subject of several recent research reports. Goldman Sachs Group initiated coverage on shares of Autolus Therapeutics in a report on Thursday, July 26th. They set a “neutral” rating for the company. William Blair initiated coverage on shares of Autolus Therapeutics in a report on Tuesday, July 17th. They set an “outperform” rating for the company. Wells Fargo & Co initiated coverage on shares of Autolus Therapeutics in a report on Tuesday, July 17th. They set an “outperform” rating and a $38.00 target price for the company. Finally, Jefferies Financial Group began coverage on shares of Autolus Therapeutics in a report on Tuesday, July 17th. They set a “buy” rating and a $37.00 target price for the company.

NASDAQ:AUTL opened at $24.65 on Thursday. Autolus Therapeutics has a 1-year low of $19.17 and a 1-year high of $33.50.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Woodford Investment Management Ltd purchased a new stake in Autolus Therapeutics in the 2nd quarter worth $42,643,000. Baker BROS. Advisors LP purchased a new stake in Autolus Therapeutics in the 2nd quarter worth $6,304,000. Partner Fund Management L.P. purchased a new stake in Autolus Therapeutics in the 2nd quarter worth $5,301,000. Aquilo Capital Management LLC purchased a new stake in Autolus Therapeutics in the 2nd quarter worth $4,018,000. Finally, Millennium Management LLC purchased a new stake in Autolus Therapeutics in the 2nd quarter worth $3,910,000. 21.06% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

See Also: How is an ETF different from a mutual fund?

Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply